Shanghai, China – December 21– MicroPort CardioFlow Medtech Corporation (02160.HK, "MicroPort® CardioFlow") today announced the completion of its strategic merger with MicroPort® Cardiac Rhythm Management ("MicroPort® CRM"). Following the closing of the transaction, MicroPort® CRM is now a wholly owned subsidiary of MicroPort® CardioFlow.
Following the merger, the two businesses will operate under a unified management system and fully merge the device-based therapy capabilities in the structural heart intervention field with the strengths in continuous monitoring and data insights from the cardiac rhythm management field. This integration positions the merged company to advance into the heart failure sector in order to jointly build a cardiac solution platform spanning structural heart intervention, rhythm management, and heart failure care.
This convergence comes at a time when heart failure care is shifting from episodic intervention toward longitudinal, data-driven management with increased importance on continuous monitoring and coordinated clinical decision-making. Heart failure is widely recognized as the "cancer" of cardiovascular disease due to its high prevalence, complex etiology, and poor long-term prognosis. According to the World Health Organization, the global heart failure patient population will reach nearly 65 million in 2025 with a five-year survival rate below 50%. Despite the vast patient base and complex disease etiologies, the penetration rate of device-based therapy for heart failure remains relatively low.
The new MicroPort® CardioFlow will build on this opportunity by leveraging existing leadership in China’s TAVI market and its comprehensive valve-focused innovation pipeline, combined with MicroPort® CRM’s over 60 years of expertise, 12 core product pipelines, and a portfolio of over 40 globally commercialized products, providing a foundation to develop end-to-end solutions across heart failure etiologies and disease stages.
Mr. Zhu Xiaoming, President of Soaring CRM (China Business), stated: " We are honored to be part of MicroPort® CardioFlow. While steadfastly upholding our commitment to delivering high-quality products and services to the existing stakeholders of our respective offerings, we will integrate and optimize our post-globalization resources. Soaring CRM is ready, and we expect to work side by side to build the future."
Mr. Philippe Wanstok, President of MicroPort® CRM (International Business), stated: " We will empower each other, integrate and optimize global resources, and combine our extensive local operational experience to accelerate the global rollout of innovative products and comprehensive solutions, thereby providing more integrated and higher-quality services to patients worldwide."
Mr. Zhang Ruinian, President of MicroPort® CardioFlow, stated: "Post-merger, we not only possess a globally established product portfolio but have also formed a complete capability loop—from structural intervention therapy to long-term rhythm management, and further to whole-process heart failure monitoring. We will accelerate the translation of these synergistic advantages into tangible, accessible clinical value."
Dr. Brian Chang, Chief Medical Officer of MicroPort® Group and Co-Chairman of the Board of MicroPort® CardioFlow, stated: " This merger is a crucial step in the MicroPort® Group's strategic layout focused on complex cardiovascular diseases such as heart failure. We will fully leverage the Group’s cross-business synergy and global resources to provide physicians and patients with innovative heart failure management solutions that cover 'all etiologies, all stages, and the entire care cycle,' striving to become a leader in emerging technologies for the diagnosis and treatment of heart failure."
Mr. Chen Guoming, Chairman of the Board of MicroPort® CardioFlow, stated: “The integration of the cardiovascular business is a key strategic initiative for MicroPort® CardioFlow to more closely align device innovation with the clinical practice of cardiovascular disease. We will fully integrate the global resource networks and core technologies of both parties, translating our broad technology portfolio into tangible and sustainable clinical value to benefit patients globally.”